Manufacturer
ANTAH PHARMA SDN. BHD.
Contents
Ciprofloxacin
Indication
Prophylaxis of meningococcal meningitis, Gonococcal cervicitis, Gonococcal urethritis, Intra-abdominal infections, Diarrhoea, Epididymo-orchitis, Pelvic inflammatory disease, Bone and joint infections, Complicated cystitis, Cystic fibrosis, Uncomplicated cystitis, Pyelonephritis, Prostatitis, Typhoid fever, Malignant otitis externa, Lower respiratory tract infections, Skin and soft tissue infections, Upper respiratory tract infections and Treatment and postexposure prophylaxis of inhalation anthrax
Instruction
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Drug interaction
Increased risk of prolonged QT interval with Class IA (e.g. quinidine, procainamide) and Class III (e.g. amiodarone, sotalol) antiarrhythmics, TCA, macrolides (e.g. erythromycin), cisapride, antipsychotics. Increased serum concentration with probenecid. May increase serum concentration and toxicity of methotrexate; CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline); xanthine derivatives (e.g. caffeine, pentoxifylline). Increased risk of tendon disorders with corticosteroids. Increased serum creatinine with cyclosporin. Increased risk of convulsions with NSAIDs. May alter serum concentrations of phenytoin. Reduced oral absorption with products containing multivalent cations (e.g. Al, Ca, Mg, Fe). May increase anticoagulant effect of vit K, warfarin.Potentially Fatal: May increase serum concentration and potentiate hypotensive and sedative effects of tizanidine. Rarely, serious and fatal seizures, status epilepticus, cardiac arrest, respiratory failure with theophylline.
Malaysia
